Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials

A. R. Müller, B. den Hollander, P. M. van de Ven, K. C.B. Roes, L. Geertjens, H. Bruining, C. D.M. van Karnebeek, F. E. Jansen, M. C.Y. de Wit, L. W. ten Hoopen, A. B. Rietman, B. Dierckx, F. A. Wijburg, E. Boot, M. M.G. Brands, A. M. van Eeghen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials'. Together they form a unique fingerprint.

Psychology

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Neuroscience